Skip to main content

Table 2 SMAD4 expression in the validation cohort and correlation with clinicopathological patient characteristics (*insignificant after correction for multiple testing)

From: Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine

    

SMAD4 cytoplasmatic expression

SMAD4 nuclear expression

  

Total valid

Q123

Q4

 

HScore 0 present

HScore 0 absent

  

n

(%)

n

(%)

n

(%)

p value

n

(%)

n

(%)

p value

Total

Total

463

(100)

366

(79.1)

97

(20.9)

 

263

(56.8)

200

(43.2)

 

Gender

Female

178

(38.4)

144

(80.9)

34

(19.1)

0.482

90

(50.6)

88

(49.4)

0.034

 

Male

285

(61.6)

222

(77.9)

63

(22.1)

 

173

(60.7)

112

(39.3)

 

Age group

< 68 years

232

(50.1)

190

(81.9)

42

(18.1)

0.139

131

(56.5)

101

(43.5)

0.925

 

≥ 68 years

231

(49.9)

176

(76.2)

55

(23.8)

 

132

(57.1)

99

(42.9)

 

Localization

Proximal stomach

145

(31.0)

123

(84.8)

22

(15.2)

0.049

93

(64.1)

52

(35.9)

0.033*

 

Distal stomach

318

(69.0)

243

(76.4)

75

(23.6)

 

170

(53.5)

148

(46.5)

 

Laurén phenotype

Intestinal

237

(51.2)

186

(78.5)

51

(21.5)

0.313

149

(62.9)

88

(37.1)

0.026

Diffuse

147

(31.7)

122

(83.0)

25

(17.0)

 

73

(49.7)

74

(50.3)

 
 

Mixed

31

(6.7)

24

(77.4)

7

(22.6)

 

19

(61.3)

12

(38.7)

 
 

Unclassifiable

48

(10.4)

34

(70.8)

14

(29.2)

 

22

(45.8)

26

(54.2)

 

Grading

G1 / G2

107

(23.1)

82

(76.6)

25

(23.4)

0.499

62

(57.9)

45

(42.1)

0.824

 

G3 / G4

356

(76.9)

284

(79.8)

72

(20.2)

 

201

(56.5)

155

(43.5)

 

pT category

T1a / T1b

58

(12.5)

38

(65.5)

20

(34.5)

0.011*

32

(55.2)

26

(44.8)

0.923

 

T2

53

(11.4)

38

(71.7)

15

(28.3)

 

28

(52.8)

25

(47.2)

 
 

T3

182

(39.3)

150

(82.4)

32

(17.6)

 

108

(59.3)

74

(40.7)

 
 

T4a / T4b

170

(36.7)

140

(82.4)

30

(17.6)

 

95

(55.9)

75

(44.1)

 

pN category

N0

132

(28.5)

99

(75.0)

33

(25.0)

0.151

69

(52.3)

63

(47.7)

0.399

 

N1

63

(13.6)

48

(76.2)

15

(23.8)

 

39

(61.9)

24

(38.1)

 
 

N2

85

(18.4)

70

(82.4)

15

(17.6)

 

49

(57.6)

36

(42.4)

 
 

N3a/b

182

(39.4)

148

(81.3)

34

(18.7)

 

106

(58.2)

76

(41.8)

 

M category

M0

376

(81.2)

291

(77.4)

85

(22.6)

0.079

217

(57.7)

159

(42.3)

0.471

 

M1

87

(18.8)

75

(86.2)

12

(13.8)

 

46

(52.9)

41

(47.1)

 

UICC stage

IA / IB

79

(17.1)

55

(69.6)

24

(30.4)

0.011*

40

(50.6)

39

(49.4)

0.832

 

IIA / IIB

99

(21.4)

77

(77.8)

22

(22.2)

 

59

(59.6)

40

(40.4)

 
 

IIIA / IIIB / IIIC

197

(42.6)

158

(80.2)

39

(19.8)

 

118

(59.9)

79

(40.1)

 
 

IV

87

(18.8)

75

(86.2)

12

(13.8)

 

46

(52.9)

41

(47.1)

 

Lymph node ratio

Low (< 0.189)

226

(48.9)

175

(77.4)

51

(22.6)

0.426

126

(55.8)

100

(44.2)

0.639

High (≥ 0.189)

236

(51.1)

190

(80.5)

46

(19.5)

 

137

(58.1)

99

(41.9)

 

pL category

L0

216

(48.8)

167

(77.3)

49

(22.7)

0.645

112

(51.9)

104

(48.1)

0.069

 

L1

227

(51.2)

180

(79.3)

47

(20.7)

 

138

(60.8)

89

(39.2)

 

pV category

V0

393

(88.9)

308

(78.4)

85

(21.6)

0.856

225

(57.3)

168

(42.7)

0.446

 

V1

49

(11.1)

38

(77.6)

11

(22.4)

 

25

(51.0)

24

(49.0)

 

R status

R0

400

(87.3)

311

(77.8)

89

(22.3)

0.170

230

(57.5)

170

(42.5)

0.479

 

R1 / R2

58

(12.7)

50

(86.2)

8

(13.8)

 

30

(51.7)

28

(48.3)

 

HER2 status

Negative

397

(91.9)

320

(80.6)

77

(19.4)

0.657

227

(57.2)

170

(42.8)

> 0.999

 

Positive

35

(8.1)

27

(77.1)

8

(22.9)

 

20

(57.1)

15

(42.9)

 

H. pylori status

Negative

330

(84.6)

261

(79.1)

69

(20.9)

0.092

189

(57.3)

141

(42.7)

0.207

 

Positive

60

(15.4)

41

(68.3)

19

(31.7)

 

29

(48.3)

31

(51.7)

 

EBV status

Negative

428

(95.5)

341

(79.7)

87

(20.3)

0.273

242

(56.5)

186

(43.5)

0.821

 

Positive

20

(4.5)

14

(70.0)

6

(30.0)

 

12

(60.0)

8

(40.0)

 

MSI status

MSS

412

(92.2)

332

(80.6)

80

(19.4)

0.008*

236

(57.3)

176

(42.7)

0.375

 

MSI

35

(7.8)

21

(60.0)

14

(40.0)

 

17

(48.6)

18

(51.4)

 

p53 status

Quartile 1/Quartile 4

226

(49.8)

186

(82.3)

40

(17.7)

0.163

145

(64.2)

81

(35.8)

0.003

 

Quartile 2/Quartile 3

228

(50.2)

175

(76.8)

53

(23.2)

 

115

(50.4)

113

(49.6)

 

Overall survival [months]

Total / events / censored

451

 

347 / 289 / 68

94 / 62 / 32

0.001

257 / 210 / 47

194 / 141 / 53

0.035*

Median survival

  

13.4 ± 1.1

22.4 ± 7.0

 

14.9 ± 1.4

15.6 ± 1.9

 

95% C.I.

  

11.3–15.5

8.7–36.0

 

12.2–17.6

12.9–17.1

 

Tumor-specific survival [months]

Total / events / censored

423

 

333 / 236 / 97

90 / 51 / 39

0.002

240 / 173 / 67

183 / 114 / 69

0.038*

Median survival

  

14.7 ± 1.4

30.3 ± 7.5

 

15.5 ± 1.6

18.4 ± 2.7

 

95% C.I.

  

12.0–17.3

15.5–45.0

 

12.4–18.5

13.1–23.8

Â